A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor.
Phase of Trial: Phase II
Latest Information Update: 13 May 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2011 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.